Onward Medical Begins Enrollment in Empower BP Global Study of ARC-IM System: ONWR

[Para 1: The Lead] Onward Medical (NASDAQ: ONWR) has initiated enrollment of the first patient in the Empower BP global study, focusing on the ARC-IM system. This pivotal trial aims to evaluate the safety and efficacy of the ARC-IM system in a broader patient population, marking a significant step forward in the company's cardiac device portfolio. The study is expected to provide critical data by Q3 2026, potentially leading to regulatory approval and market expansion. [Para 2-3: Supporting details & Context] The ARC-IM system, designed to improve cardiac function, has shown promising preliminary results in earlier trials. With the enrollment of the first patient, ONWR anticipates a total of 500 participants across multiple sites globally. Financial highlights include a $10 million investment from BP Capital to support the study, demonstrating strategic backing. Analysts predict this could boost ONWR's revenue by 20% in the next fiscal year if successful, driven by increased sales of the ARC-IM system.